Friday, July 10, 2026

pharma · Hypertension · Breast Neoplasms

Pfizer

Pfizer is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include Hypertension, Breast Neoplasms, Complicated Intra-abdominal Infection, Non-Small Cell Lung Cancer, Arthritis, Rheumatoid

New York 10017, US HQ
103,316 Employees
EMA registrant Type
Company details
Clinical program

inotuzumab ozogamicin-dose level 2

Approved · small molecule · Leukemia

inotuzumab ozogamicin-dose level 2 for Leukemia is a Approved program (small_molecule) at Pfizer with 1 ClinicalTrials.gov record(s).

← All Pfizer projects Approved small molecule completed

Internal code B1931030

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Pfizer
Phase
Approved
Modality
small_molecule
Indication
Leukemia
Status
completed
Trials
1